Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Glenmark Pharmaceuticals Ltd Option Chain

1,378.1
(0.13%)
Apr 11, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Ol (lots)Call PriceStrike PricePut PriceOl (lots)
7250%₹562.050%1,140--
7,975-8.33%₹499.15-1.86%1,200₹0.05-80%66,700-2.12%
--1,220₹0.350%10,1500%
--1,240₹0.05-91.66%10,1500%
--1,260₹0.10%19,5750%
2,9000%₹1700%1,280₹0.40%4,3500%
15,9500%₹399.45-2.13%1,300₹0.05-66.66%68,1500%
2,1750%₹160.90%1,320₹0.1550%29,725-4.65%
2,900300%₹363-0.81%1,340₹0.05-66.66%52,925-2.66%
7,9750%₹149.10%1,360₹0.05-50%81,9250%
7250%₹134.750%1,380₹0.150%28,2750%
42,050-19.44%₹293-5.08%1,400₹0.10%1,40,650-19.16%
27,550-11.62%₹276-3.15%1,420₹0.05-66.66%39,150-10%
53,650-23.71%₹260-2.8%1,440₹0.050%1,05,125-7.64%
76,125-5.40%₹235-2.08%1,460₹0.10%76,125-22.22%
55,825-4.93%₹218.65-4.51%1,480₹0.150%75,400-8.77%
1,02,950-30.39%₹225.359.92%1,500₹0.05-66.66%2,97,250-12.39%
89,175-4.65%₹181.551.99%1,520₹0.05-50%1,15,275-12.15%
1,39,925-7.21%₹153.95-8.33%1,540₹0.05-50%72,500-35.89%
90,625-13.19%₹136-8.1%1,560₹0.05-50%1,45,725-2.89%
69,600-23.80%₹114.6-4.46%1,580₹0.150%1,15,275-3.63%
1,95,025-24.43%₹85.5-20.61%1,600₹0.05-75%2,34,900-26.36%
73,950-11.30%₹75-12.94%1,620₹0.05-50%2,34,900-3.28%
92,075-16.99%₹62-6.34%1,640₹0.05-87.5%1,48,625-19.29%
74,675-14.16%₹34-27.96%1,660₹0.05-91.66%1,87,050-29.12%
62,350-58.04%₹15.65-44.99%1,680₹0.05-94.11%1,13,825-54.62%
1,16,000-65.06%₹0.05-99.5%1,700₹11.7397.87%1,26,150-69.20%
1,32,675-22.78%₹0.05-97.72%1,720₹30106.18%52,200-14.28%
56,550-49.35%₹0.05-94.11%1,740₹300%1,4500%
38,425-49.03%₹0.05-91.66%1,760--
22,475-13.88%₹0.05-87.5%1,780--
17,400-48.93%₹0.05-75%1,800--
12,325-29.16%₹0.050%1,840--
7250%₹0.750%1,880--

Glenmark Pharma.: Related NEWS

Glenmark Pharma Appoints Anurag Mantri as New CFO
7 Apr 2025|12:21 PM

The reshuffle comes after VS Mani, the company's current chief, announced early retirement; he will officially retire as chief on May 26, 2025 after an eight-year career with the company.

Read More
Glenmark Gets USFDA Nod for Olopatadine Ophthalmic Solution
23 Mar 2025|11:40 AM

This approval would allow Glenmark Therapeutics Inc., USA to market the product in the US market and would further fortify its ophthalmic portfolio.

Read More
Glenmark Expands US Portfolio with Acetylcysteine Injection Launch
3 Mar 2025|09:57 PM

Acetylcysteine Injection will be launched in 6 gm/30 mL (200 mg/mL) single-dose vials, and will be made available to hospitals and other system-wide healthcare providers.

Read More
Glenmark Pharma Settles US Legal Dispute Over Generic Zetia
24 Feb 2025|04:15 PM

The lawsuits included one on a generic version of Zetia, a cholesterol drug, as well as four other lawsuits involving Vytorin, a combination drug that contains Zetia.

Read More
Glenmark Pharma Q3 Revenue Jumps 35% to ₹3,388 Crore
16 Feb 2025|10:34 PM

EBITDA surged to ₹600.3 crore, up from a loss of ₹208.7 crore in the year-ago quarter, indicating better operational efficiency

Read More
Glenmark Hit with ₹121.25 Crore Tax Demand, Company to Appeal
10 Feb 2025|09:25 AM

It also appropriates ₹5.86 crore that Glenmark had already paid for surrendering IGST refunds relating to non-realisation of export proceeds.

Read More
Glenmark Launches Generic Glaucoma Drug
27 Nov 2024|12:23 PM

According to a statement from the firm, the Travoprost ophthalmic solution (0.004% ionic buffered solution) is both bioequivalent and therapeutically equivalent to the reference listed medication

Read More
Glenmark Pharmaceuticals Posts ₹354.4 Crore Profit in Q2
18 Nov 2024|10:45 AM

The company also reported revenue from operations to ₹3433.7 Crore. The EBITDA margin for the quarter that ended on September 30, 2024 stands at 17.5%.

Read More
Glenmark Recalls US Products Over Manufacturing Issues
14 Oct 2024|01:22 PM

Glenmark Pharmaceuticals Inc, USA, issued a countrywide (US) Class II recall on September 24 this year.

Read More
Glenmark Pharmaceuticals' Aurangabad Facility Passes FDA Inspection
23 Sep 2024|01:08 PM

This positive outcome indicates compliance with FDA standards and enhances Glenmark's credibility in the pharmaceutical sector.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.